OVERVIEW

Warm Autoimmune Hemolytic Anemia (WAIHA) is organized by American Academy of CME, Inc., CheckRare.

Released On: June 1, 2023
Expires On: May 31, 2024

Program Overview
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis. Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new therapies under investigation which may impact treatment in the future. This 60-minute CME program, hosted by Irina Murakhovskaya, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in New York, NY and Bruno Fattizzo, MD, of the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in Milan, Italy, describes current best practices for diagnosing and managing patients with wAIHA.

Learning Objectives
After participating in the activity, learners should be better able to:
• Describe the difference between primary and secondary wAIHA
• List best practices for diagnosing wAIHA
• Describe common complications associated with wAIHA
• Explain current treatment recommendations for patients with wAIHA and the evidence which supports them
• Describe potential therapies in development for treating patients with wAIHA

Additional details will be posted as soon as information is available.